Publication date: Dec 01, 2024
During the COVID-19 pandemic, it has been observed that acute kidney injury (AKI) especially requiring intervention support of hemodialysis has notably increased mortality rates among COVID-19-positive critically ill patients; however, comprehensive data regarding this from India, especially the eastern territory, remains sparse. This study aims to outline the demographic, clinical, and biochemical characteristics, along with the outcomes, of these patients. A retrospective study was performed at the All India Institute of Medical Sciences (AIIMS), Patna, from March 1, 2020, to March 31, 2021. Included were patients diagnosed with COVID-19 and AKI necessitating hemodialysis during their intensive care unit (ICU) stay. These patients tested positive for COVID-19 and met the Kidney Disease: Improving Global Outcomes (KDIGO) criteria for AKI stages 1-3, requiring ICU admission and hemodialysis. Medical history, clinical features, laboratory results, comorbidities, and demographic data were collected and analyzed. Patients were tracked from admission to discharge or death. Gaussian-distributed values were compared using the unpaired t-test or Pearson’s test, while non-Gaussian continuous variables were analyzed using the Mann-Whitney test or Spearman’s test. The study employed the Kolmogorov-Smirnov test to assess Gaussian distribution, while categorical data were compared using the Chi-square test. Among 773 patients with positive COVID-19 tests who were admitted to the ICU, 236 patients developed AKI, and among them, 139 patients required hemodialysis. The total mortality rate was 167 (70. 7%) among people who had AKI and 102 (77%) in patients with AKI who required hemodialysis. AKI was also a risk factor associated with higher mortality rates in older patients (>45 years) (n=150 (73. 2%)), those needing invasive ventilation (n=163 (88. 1%)), and patients with elevated total leucocyte count (TLC) (n=130 (79. 3%)), lactate dehydrogenase (LDH) (n=159 (72. 9%)), interleukin-6 (IL-6) (n=153 (72. 2%)), and serum ferritin (n=51 (73. 7%)) and hypoalbuminemia (n=152 (73. 1%)). AKI requiring hemodialysis significantly increases mortality risk in COVID-19 patients. Other risk factors for mortality with AKI in COVID-19-positive patients include age, elevated leucocyte count, invasive ventilation, and deranged inflammatory markers.
Concepts | Keywords |
---|---|
Hemodialysis | acute kidney injury |
Kidney | covid-19 |
Spearman | hemodialysis |
intensive care | |
mortality | |
risk factor |
Semantics
Type | Source | Name |
---|---|---|
disease | MESH | COVID-19 |
disease | MESH | Infection |
disease | MESH | Acute Kidney Injury |
disease | IDO | intervention |
disease | MESH | critically ill |
drug | DRUGBANK | Methionine |
disease | MESH | Kidney Disease |
disease | IDO | history |
disease | MESH | death |
disease | MESH | hypoalbuminemia |